Lucigen Corp.

Belkins
Lucigen provides products and services to support NGS, protein expression, and molecular biology applications in an ISO 13485 compliant environment. With a focus on quality and customer service, we strive to make your time in the laboratory productive and successful.

Related News

FIRMENICH OPENS NEW BIOTECHNOLOGY AND NATURALS PILOT PLANT AND LABORATORY IN GENEVA

Firmenich | October 01, 2020

news image

Firmenich, the world's largest privately-owned Perfume and Taste company, is proud to announce the opening of its new biotechnology and naturals pilot plant and laboratory in Geneva. Benefiting from the latest digital technology, the facility opens a new era for the development of ingredients and clean label solutions by providing faster speed-to-market and greater flexibility for customer collaboration. Integrated into the Group's flagship ingredients production site at La Plaine, Genev...

Read More

CELL AND GENE THERAPY

AMYRIS PARTNERS WITH INSCRIPTA TO ENHANCE DEVELOPMENT OF SUSTAINABLE INGREDIENTS USING THE ONYX™ GENOME ENGINEERING PLATFORM

Amyris | October 06, 2021

news image

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced that Amyris has licensed the Onyx genome engineering platform from Inscripta, a leading gene editing technology company. Amyris and Inscripta will also explore joint research and development opportunities to expand the Onyx platform functionality. Amyris' prod...

Read More

INDUSTRIAL IMPACT

PARTEK AND AGILENT PARTNER TO DELIVER ALISSA CUSTOMERS END-TO-END BIOINFORMATICS WORKFLOW

Partek® Incorporated | August 20, 2021

news image

Partek® Incorporated announced today they have entered into an agreement with Agilent to integrate Partek® Flow® bioinformatics software with the Agilent Alissa Clinical Informatics Platform. This integration delivers a complete end-to-end analysis workflow that is robust, flexible, and customizable to meet Agilent customer demands. Partek has also made available the Agilent pipeline for RNA-Seq inside Partek Flow. In addition, the agreement allows Agilent to resell Partek Flow softw...

Read More

CELL AND GENE THERAPY

THROUGH CUTTING-EDGE MRNA AND AI TECHNOLOGY PLATFORMS, I-MAB EXPANDS ITS EMERGING PORTFOLIO OF NEXT-GENERATION NOVEL ONCOLOGY THERAPEUTICS

I-Mab | July 12, 2021

news image

I-Mab, a clinical-stage biopharmaceutical business dedicated to discovering, developing, and commercialization of novel biologics, announced today the signing of two new partnerships with Chinese emerging biotech firms to enhance its next-generation innovation pipeline. Collaborations with Immorna, an mRNA biotech company, and neoX Biotech, an AI-enabled R&D biotech company, provide I-Mab access to revolutionary technologies to search for new cancer treatments. I-Mab will crea...

Read More

Firmenich | October 01, 2020

news image

FIRMENICH OPENS NEW BIOTECHNOLOGY AND NATURALS PILOT PLANT AND LABORATORY IN GENEVA

Firmenich, the world's largest privately-owned Perfume and Taste company, is proud to announce the opening of its new biotechnology and naturals pilot plant and laboratory in Geneva. Benefiting from the latest digital technology, the facility opens a new era for the development of ingredients and clean label solutions by providing faster speed-to-market and greater flexibility for customer collaboration. Integrated into the Group's flagship ingredients production site at La Plaine, Genev...

Read More

CELL AND GENE THERAPY

Amyris | October 06, 2021

news image

AMYRIS PARTNERS WITH INSCRIPTA TO ENHANCE DEVELOPMENT OF SUSTAINABLE INGREDIENTS USING THE ONYX™ GENOME ENGINEERING PLATFORM

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced that Amyris has licensed the Onyx genome engineering platform from Inscripta, a leading gene editing technology company. Amyris and Inscripta will also explore joint research and development opportunities to expand the Onyx platform functionality. Amyris' prod...

Read More

INDUSTRIAL IMPACT

Partek® Incorporated | August 20, 2021

news image

PARTEK AND AGILENT PARTNER TO DELIVER ALISSA CUSTOMERS END-TO-END BIOINFORMATICS WORKFLOW

Partek® Incorporated announced today they have entered into an agreement with Agilent to integrate Partek® Flow® bioinformatics software with the Agilent Alissa Clinical Informatics Platform. This integration delivers a complete end-to-end analysis workflow that is robust, flexible, and customizable to meet Agilent customer demands. Partek has also made available the Agilent pipeline for RNA-Seq inside Partek Flow. In addition, the agreement allows Agilent to resell Partek Flow softw...

Read More

CELL AND GENE THERAPY

I-Mab | July 12, 2021

news image

THROUGH CUTTING-EDGE MRNA AND AI TECHNOLOGY PLATFORMS, I-MAB EXPANDS ITS EMERGING PORTFOLIO OF NEXT-GENERATION NOVEL ONCOLOGY THERAPEUTICS

I-Mab, a clinical-stage biopharmaceutical business dedicated to discovering, developing, and commercialization of novel biologics, announced today the signing of two new partnerships with Chinese emerging biotech firms to enhance its next-generation innovation pipeline. Collaborations with Immorna, an mRNA biotech company, and neoX Biotech, an AI-enabled R&D biotech company, provide I-Mab access to revolutionary technologies to search for new cancer treatments. I-Mab will crea...

Read More